Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julie A McEarchern

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Clinical Lymphoma & Myeloma|April 14, 2009
Novel antibody-based therapeutic agents targeting CD70: a potential approach for treating Waldenström's macroglobulinemiaChe-Leung Law, Julie A McEarchern, Iqbal S Grewal
Advances in Experimental Medicine and Biology|September 18, 2009
Targeting CD70 for human therapeutic useTamar E Boursalian, Julie A McEarchern, Che-Leung Law, et al.
Cancer Immunology, Immunotherapy : CII|July 2, 2003
Dendritic cells efficiently acquire and present antigen derived from lung cancer cells and induce antigen-specific T-cell responsesYaling Zhou, Julie A McEarchern, Edward Howard, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 1, 2012
Clinical binding properties, internalization kinetics, and clinicopathologic activity of brentuximab vedotin: an antibody-drug conjugate for CD30-positive lymphoid neoplasmsJonathan R Fromm, Julie A McEarchern, Dana Kennedy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 26, 2011
Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphomaTimothy S Lewis, Renee S McCormick, Kim Emmerton, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 28, 2009
Blocking of CD27-CD70 pathway by anti-CD70 antibody ameliorates joint disease in murine collagen-induced arthritisEzogelin Oflazoglu, Tamar E Boursalian, Weiping Zeng, et al.
Cancer Research|September 17, 2005
Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40Che-Leung Law, Kristine A Gordon, John Collier, et al.
Blood|October 14, 2006
Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activitiesJulie A McEarchern, Ezogelin Oflazoglu, Leigh Francisco, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2008
Preclinical characterization of SGN-70, a humanized antibody directed against CD70Julie A McEarchern, Leia M Smith, Charlotte F McDonagh, et al.
Blood|January 25, 2008
CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemiaAllen W Ho, Evdoxia Hatjiharissi, Bryan T Ciccarelli, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Clinical Lymphoma & Myeloma|April 14, 2009
Novel antibody-based therapeutic agents targeting CD70: a potential approach for treating Waldenström's macroglobulinemiaChe-Leung Law, Julie A McEarchern, Iqbal S Grewal
Advances in Experimental Medicine and Biology|September 18, 2009
Targeting CD70 for human therapeutic useTamar E Boursalian, Julie A McEarchern, Che-Leung Law, et al.
Cancer Immunology, Immunotherapy : CII|July 2, 2003
Dendritic cells efficiently acquire and present antigen derived from lung cancer cells and induce antigen-specific T-cell responsesYaling Zhou, Julie A McEarchern, Edward Howard, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 1, 2012
Clinical binding properties, internalization kinetics, and clinicopathologic activity of brentuximab vedotin: an antibody-drug conjugate for CD30-positive lymphoid neoplasmsJonathan R Fromm, Julie A McEarchern, Dana Kennedy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 26, 2011
Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphomaTimothy S Lewis, Renee S McCormick, Kim Emmerton, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 28, 2009
Blocking of CD27-CD70 pathway by anti-CD70 antibody ameliorates joint disease in murine collagen-induced arthritisEzogelin Oflazoglu, Tamar E Boursalian, Weiping Zeng, et al.
Cancer Research|September 17, 2005
Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40Che-Leung Law, Kristine A Gordon, John Collier, et al.
Blood|October 14, 2006
Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activitiesJulie A McEarchern, Ezogelin Oflazoglu, Leigh Francisco, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2008
Preclinical characterization of SGN-70, a humanized antibody directed against CD70Julie A McEarchern, Leia M Smith, Charlotte F McDonagh, et al.
Blood|January 25, 2008
CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemiaAllen W Ho, Evdoxia Hatjiharissi, Bryan T Ciccarelli, et al.
Pageof 2